Jorn Brouwer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jorn Brouwer has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
Martin J. Swaans
9 shared publicationsBenno J.W.M. Rensing
7 shared publicationsVincent J. Nijenhuis
6 shared publications- Vincent Johan Nijenhuis
Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands
6 shared publications Jurriën M. Ten Berg
5 shared publicationsJurrien M. Ten Berg
Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands
4 shared publications
Latest Publications
- 30 January 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (5) , 438-449
Continuation versus Interruption of Oral Anticoagulation during TAVI
One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism. We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients were randomly assigned in a 1:1 ratio to periprocedural continuation or interruption of oral anticoagulation. The primary outcome was a composite of death from cardiovascular causes, stroke from any cause, myocardial infarction, major vascular complications, or major bleeding within 30 days after TAVI. A total of 858 patients were included in the modified intention-to-treat population: 431 were assigned to continuation and 427 to interruption of oral anticoagulation. A primary-outcome event occurred in 71 patients (16.5%) in the continuation group and in 63 (14.8%) in the interruption group (risk difference, 1.7 percentage points; 95% confidence interval [CI], -3.1 to 6.6; P = 0.18 for noninferiority). Thromboembolic events occurred in 38 patients (8.8%) in the continuation group and in 35 (8.2%) in the interruption group (risk difference, 0.6 percentage points; 95% CI, -3.1 to 4.4). Bleeding occurred in 134 patients (31.1%) in the continuation group and in 91 (21.3%) in the interruption group (risk difference, 9.8 percentage points; 95% CI, 3.9 to 15.6). In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.).
- 30 January 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (5) , 438-449
Continuation versus Interruption of Oral Anticoagulation during TAVI
One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism. We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients were randomly assigned in a 1:1 ratio to periprocedural continuation or interruption of oral anticoagulation. The primary outcome was a composite of death from cardiovascular causes, stroke from any cause, myocardial infarction, major vascular complications, or major bleeding within 30 days after TAVI. A total of 858 patients were included in the modified intention-to-treat population: 431 were assigned to continuation and 427 to interruption of oral anticoagulation. A primary-outcome event occurred in 71 patients (16.5%) in the continuation group and in 63 (14.8%) in the interruption group (risk difference, 1.7 percentage points; 95% confidence interval [CI], -3.1 to 6.6; P = 0.18 for noninferiority). Thromboembolic events occurred in 38 patients (8.8%) in the continuation group and in 35 (8.2%) in the interruption group (risk difference, 0.6 percentage points; 95% CI, -3.1 to 4.4). Bleeding occurred in 134 patients (31.1%) in the continuation group and in 91 (21.3%) in the interruption group (risk difference, 9.8 percentage points; 95% CI, 3.9 to 15.6). In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.).
- 29 January 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
The Impact of Permanent Pacemaker Implantation After TAVI on Mortality and Quality of Life: A POPular TAVI Substudy
Background: Conduction disturbances are common after transcatheter aortic valve implantation (TAVI) and frequently require permanent pacemaker implantation (PPI). Data regarding its impact on mortality and morbidity are conflicting. This study aims to assess the impact of PPI before or within 30 days after TAVI on mortality and health‐related Quality of Life (QoL) during the first year after TAVI.Methods: In this POPular TAVI substudy, 978 patients were included and categorized into three groups: Neither PPI before or within 30 days after TAVI (no PPI, n = 779), PPI before TAVI (PPI pre‐TAVI, n = 102), PPI within 30 days after TAVI (PPI post‐TAVI, n = 97). All‐cause death and cardiac death were evaluated at 1 year. QoL was assessed using the SF‐12 and EQ‐5D‐5L questionnaires at baseline and 3, 6, and 12 months.Results: At 1‐year, all‐cause death was seen in 6.9% (PPI pre‐TAVI, p = 0.53) and 10.3% (PPI post‐TAVI, p = 0.66) of the patients compared to 8.7% of the patients (no PPI). Cardiac death was observed in 4.9% (PPI pre‐TAVI, p = 0.58) and 6.2% (PPI post‐TAVI, p = 0.94) of the patients compared to 6.2% of patients (no PPI). Regarding QoL, the PPI pre‐TAVI group showed lower PCS‐12 over time compared to the no PPI group (p = 0.04), while MCS‐12, EQ‐5D Index and EQ‐5D VAS scores were equal. No significant differences in QoL were seen between the PPI post‐TAVI group and the no PPI group.Conclusion: PPI before or within 30 days after TAVI was not associated with increased mortality within 1 year. PPI pre‐TAVI was associated with lower physical QoL.
- 29 January 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
The Impact of Permanent Pacemaker Implantation After TAVI on Mortality and Quality of Life: A POPular TAVI Substudy
Background: Conduction disturbances are common after transcatheter aortic valve implantation (TAVI) and frequently require permanent pacemaker implantation (PPI). Data regarding its impact on mortality and morbidity are conflicting. This study aims to assess the impact of PPI before or within 30 days after TAVI on mortality and health‐related Quality of Life (QoL) during the first year after TAVI.Methods: In this POPular TAVI substudy, 978 patients were included and categorized into three groups: Neither PPI before or within 30 days after TAVI (no PPI, n = 779), PPI before TAVI (PPI pre‐TAVI, n = 102), PPI within 30 days after TAVI (PPI post‐TAVI, n = 97). All‐cause death and cardiac death were evaluated at 1 year. QoL was assessed using the SF‐12 and EQ‐5D‐5L questionnaires at baseline and 3, 6, and 12 months.Results: At 1‐year, all‐cause death was seen in 6.9% (PPI pre‐TAVI, p = 0.53) and 10.3% (PPI post‐TAVI, p = 0.66) of the patients compared to 8.7% of the patients (no PPI). Cardiac death was observed in 4.9% (PPI pre‐TAVI, p = 0.58) and 6.2% (PPI post‐TAVI, p = 0.94) of the patients compared to 6.2% of patients (no PPI). Regarding QoL, the PPI pre‐TAVI group showed lower PCS‐12 over time compared to the no PPI group (p = 0.04), while MCS‐12, EQ‐5D Index and EQ‐5D VAS scores were equal. No significant differences in QoL were seen between the PPI post‐TAVI group and the no PPI group.Conclusion: PPI before or within 30 days after TAVI was not associated with increased mortality within 1 year. PPI pre‐TAVI was associated with lower physical QoL.
- 11 September 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (5) , 1107-1118
The impact of stroke and bleeding on mortality and quality of life during the first year after TAVI: A POPular TAVI subanalysis
Background: Bleeding and stroke are frequent complications after transcatheter aortic valve implantation (TAVI). The mortality risk associated with these events has been reported before, but data regarding their impact on health‐related quality of life (QoL) is limited.Aim: To evaluate the impact of bleeding and stroke occurring within 30 days after TAVI, on mortality and QoL during the first year after TAVI.Methods: POPular TAVI was a randomized clinical trial that evaluated the addition of clopidogrel to aspirin or oral anticoagulation in patients undergoing TAVI. Besides clinical outcomes, QoL was assessed using the Short Form‐12 and EuroQoL Five Dimensions questionnaires before, and at 3, 6, and 12 months after TAVI.Results: Major or life‐threatening bleeding occurred in 81 patients (8.3%) and was associated with an increased risk of death (hazard ratio [HR] 1.95 [95% confidence interval (CI) 1.00–3.79]); minor bleeding occurred in 104 patients (10.6%) and was not associated with mortality (HR 0.75 [95% CI 0.30–1.89]). Stroke occurred in 35 patients (3.6%) and was associated with an increased risk of death (HR 2.90 [95% CI 1.23–6.83]). Mean mental component summary (MCS‐12) scores over time were lower in patients with major or life‐threatening bleeding (p = 0.01), and similar in patients with minor bleeding, compared to patients without bleeding; mean physical component summary (PCS‐12) scores, EQ‐5D index, and visual analog scale (VAS) were similar between those patients. Mean MCS‐12 scores were lower in patients with stroke (p = 0.01), mean PCS‐12, EQ‐5D index, and VAS were similar compared to patients without stroke.Conclusion: Major or life‐threatening bleeding and stroke were associated with an increased risk of death and decreased mental QoL in the first year after TAVI.
- 11 September 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (5) , 1107-1118
The impact of stroke and bleeding on mortality and quality of life during the first year after TAVI: A POPular TAVI subanalysis
Background: Bleeding and stroke are frequent complications after transcatheter aortic valve implantation (TAVI). The mortality risk associated with these events has been reported before, but data regarding their impact on health‐related quality of life (QoL) is limited.Aim: To evaluate the impact of bleeding and stroke occurring within 30 days after TAVI, on mortality and QoL during the first year after TAVI.Methods: POPular TAVI was a randomized clinical trial that evaluated the addition of clopidogrel to aspirin or oral anticoagulation in patients undergoing TAVI. Besides clinical outcomes, QoL was assessed using the Short Form‐12 and EuroQoL Five Dimensions questionnaires before, and at 3, 6, and 12 months after TAVI.Results: Major or life‐threatening bleeding occurred in 81 patients (8.3%) and was associated with an increased risk of death (hazard ratio [HR] 1.95 [95% confidence interval (CI) 1.00–3.79]); minor bleeding occurred in 104 patients (10.6%) and was not associated with mortality (HR 0.75 [95% CI 0.30–1.89]). Stroke occurred in 35 patients (3.6%) and was associated with an increased risk of death (HR 2.90 [95% CI 1.23–6.83]). Mean mental component summary (MCS‐12) scores over time were lower in patients with major or life‐threatening bleeding (p = 0.01), and similar in patients with minor bleeding, compared to patients without bleeding; mean physical component summary (PCS‐12) scores, EQ‐5D index, and visual analog scale (VAS) were similar between those patients. Mean MCS‐12 scores were lower in patients with stroke (p = 0.01), mean PCS‐12, EQ‐5D index, and VAS were similar compared to patients without stroke.Conclusion: Major or life‐threatening bleeding and stroke were associated with an increased risk of death and decreased mental QoL in the first year after TAVI.
- Open Access
- 1 January 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (1) , e012538
Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.
- 1 January 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (1) , e012538
Open AccessTemporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.
- Open Access
- 1 November 2021
- Published by Elsevier in Structural Heart
- Vol. 5 (6) , 621-630
Patient-Specific Computer Simulation to Optimize Transcatheter Heart Valve Sizing and Positioning in Bicuspid Aortic Valve
Background Outcomes of transcatheter aortic valve replacement (TAVR) in bicuspid aortic valve (BAV) might be improved through better transcatheter heart valve (THV) sizing and positioning. Patient-specific computer simulation may be used to identify an optimal THV size and implant depth that minimizes paravalvular regurgitation. We sought to examine whether the usage of optimal THV sizing and positioning would be associated with improved clinical outcomes. Methods A multi-center retrospective study was performed on patients who had undergone TAVR in BAV. Finite element models of the aortic root were created and then finite element analysis was performed using different THV sizes and implant depths. Computational fluid dynamics was undertaken. Patients were classified as having optimal THV sizing and positioning if the predicted paravalvular regurgitation of the computer simulation corresponding to the implanted THV size and implant depth was within 5 mL/sec of the best possible computer simulation, and non-optimal if not. Clinical outcomes were compared between the two patient groups. Results A total of 50 patients were included in the study. Paravalvular regurgitation severity was higher in patients where non-optimal THV sizing and positioning was used (P < 0.001). At 2 years, the Kaplan-Meier estimate of the rate of death from any cause was higher in the group where non-optimal THV sizing and positioning was used (34.5% vs. 9.1%; hazard ratio, 6.23; 95% confidence interval, 1.04 to 37.44; P = 0.02 by log-rank test). Conclusion Computer simulation suggests that the usage of optimal THV sizing and positioning might improve clinical outcomes of TAVR in BAV. Abbreviations AUC: area under the receiver operating characteristic curve; BAV: bicuspid aortic valve; BAVi: bicuspid aortic valve imaging; CI: confidence interval; CPI: contact pressure index; CT: computed tomography; TAVR: transcatheter aortic valve replacement; THV: transcatheter heart valve
- 1 November 2021
- Published by Elsevier in Structural Heart
- Vol. 5 (6) , 621-630
Open AccessPatient-Specific Computer Simulation to Optimize Transcatheter Heart Valve Sizing and Positioning in Bicuspid Aortic Valve
Background Outcomes of transcatheter aortic valve replacement (TAVR) in bicuspid aortic valve (BAV) might be improved through better transcatheter heart valve (THV) sizing and positioning. Patient-specific computer simulation may be used to identify an optimal THV size and implant depth that minimizes paravalvular regurgitation. We sought to examine whether the usage of optimal THV sizing and positioning would be associated with improved clinical outcomes. Methods A multi-center retrospective study was performed on patients who had undergone TAVR in BAV. Finite element models of the aortic root were created and then finite element analysis was performed using different THV sizes and implant depths. Computational fluid dynamics was undertaken. Patients were classified as having optimal THV sizing and positioning if the predicted paravalvular regurgitation of the computer simulation corresponding to the implanted THV size and implant depth was within 5 mL/sec of the best possible computer simulation, and non-optimal if not. Clinical outcomes were compared between the two patient groups. Results A total of 50 patients were included in the study. Paravalvular regurgitation severity was higher in patients where non-optimal THV sizing and positioning was used (P < 0.001). At 2 years, the Kaplan-Meier estimate of the rate of death from any cause was higher in the group where non-optimal THV sizing and positioning was used (34.5% vs. 9.1%; hazard ratio, 6.23; 95% confidence interval, 1.04 to 37.44; P = 0.02 by log-rank test). Conclusion Computer simulation suggests that the usage of optimal THV sizing and positioning might improve clinical outcomes of TAVR in BAV. Abbreviations AUC: area under the receiver operating characteristic curve; BAV: bicuspid aortic valve; BAVi: bicuspid aortic valve imaging; CI: confidence interval; CPI: contact pressure index; CT: computed tomography; TAVR: transcatheter aortic valve replacement; THV: transcatheter heart valve
- Open Access
- 20 April 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (8) , e019604
Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient‐Level Meta‐Analysis
Background: In patients undergoing transcatheter aortic valve implantation without an indication for oral anticoagulation, it is unclear whether single or dual antiplatelet therapy (DAPT) is necessary to minimize both the bleeding and thromboembolic risk. In this patient‐level meta‐analysis, we further investigate the effect of aspirin alone compared with DAPT for preventing both thromboembolic and bleeding events after transcatheter aortic valve implantation. Methods and Results: We conducted a systematic review of all available randomized controlled trials comparing aspirin with DAPT. In total, 1086 patients were included across 4 eligible trials. The primary outcomes were the composite of all‐cause mortality, major or life‐threatening bleeding, stroke or myocardial infarction (first composite outcome), and the same composite excluding bleeding (second composite outcome), both tested at 30 days and 3 months. The first composite outcome occurred significantly less in the aspirin‐alone group at 30 days (10.3% versus 14.7%, odds ratio [OR], 0.67; 95% CI, 0.46–0.97, P =0.034) and 3 months (11.0% versus 16.5%, hazard ratio [HR], 0.66; 95% CI, 0.47–0.94, P =0.02), compared with the DAPT group. The second composite outcome occurred in 5.5% and 6.6% at 30 days (OR, 0.83; 95% CI, 0.50–1.38, P =0.47) and in 6.9% and 8.5% at 3 months in the aspirin‐alone group compared with the DAPT group (HR, 0.82; 95% CI, 0.52–1.29, P =0.39), respectively. Conclusions: In patients without an indication for oral anticoagulation undergoing transcatheter aortic valve implantation, aspirin alone significantly reduced the composite of thromboembolic and bleeding events, and does not increase the composite of thromboembolic events after transcatheter aortic valve implantation, compared with DAPT.
- 20 April 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (8) , e019604
Open AccessAspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient‐Level Meta‐Analysis
Background: In patients undergoing transcatheter aortic valve implantation without an indication for oral anticoagulation, it is unclear whether single or dual antiplatelet therapy (DAPT) is necessary to minimize both the bleeding and thromboembolic risk. In this patient‐level meta‐analysis, we further investigate the effect of aspirin alone compared with DAPT for preventing both thromboembolic and bleeding events after transcatheter aortic valve implantation. Methods and Results: We conducted a systematic review of all available randomized controlled trials comparing aspirin with DAPT. In total, 1086 patients were included across 4 eligible trials. The primary outcomes were the composite of all‐cause mortality, major or life‐threatening bleeding, stroke or myocardial infarction (first composite outcome), and the same composite excluding bleeding (second composite outcome), both tested at 30 days and 3 months. The first composite outcome occurred significantly less in the aspirin‐alone group at 30 days (10.3% versus 14.7%, odds ratio [OR], 0.67; 95% CI, 0.46–0.97, P =0.034) and 3 months (11.0% versus 16.5%, hazard ratio [HR], 0.66; 95% CI, 0.47–0.94, P =0.02), compared with the DAPT group. The second composite outcome occurred in 5.5% and 6.6% at 30 days (OR, 0.83; 95% CI, 0.50–1.38, P =0.47) and in 6.9% and 8.5% at 3 months in the aspirin‐alone group compared with the DAPT group (HR, 0.82; 95% CI, 0.52–1.29, P =0.39), respectively. Conclusions: In patients without an indication for oral anticoagulation undergoing transcatheter aortic valve implantation, aspirin alone significantly reduced the composite of thromboembolic and bleeding events, and does not increase the composite of thromboembolic events after transcatheter aortic valve implantation, compared with DAPT.
- 14 January 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , 1462-1469
The effect of transcatheter aortic valve implantation approaches on mortality
Objectives: We aimed to evaluate the effect of transcatheter aortic valve implantation (TAVI) approaches on mortality and identify effect modifiers and predictors for mortality.Background: Alternative access routes to transfemoral (TF) TAVI include the surgical intra‐thoracic direct‐aortic (DA) and transapical (TA) approach. TA TAVI has been associated with a higher mortality rate. We hypothesized that this is related to effect modifiers, in particular the left ventricular ejection fraction (LVEF).Methods: This multicentre study derived its data from prospective registries. To adjust for confounders, we used propensity‐score based, stabilized inverse probability weighted Cox regression models.Results: In total, 5,910 patients underwent TAVI via TF (N = 4,072), DA (N = 524), and TA (N = 1,314) access. Compared to TF, 30‐day mortality was increased among DA (HR 1.87, 95%CI 1.26–2.78, p = .002) and TA (HR 3.34, 95%CI 2.28–4.89, p < .001) cases. Compared to TF, 5‐year mortality was increased among TA cases (HR 1.50, 95%CI 1.24–1.83, p < .001). None of the variables showed a significant interaction between the approaches and mortality. An impaired LVEF (≤35%) increased mortality in all approaches.Conclusions: The surgical intra‐thoracic TA and DA TAVI are both associated with a higher 30‐day mortality than TF TAVI. TA TAVI is associated with a higher 5‐year mortality than TF TAVI. The DA approach may therefore have some advantages over the TA approach when TF access is not feasible.
- 14 January 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , 1462-1469
The effect of transcatheter aortic valve implantation approaches on mortality
Objectives: We aimed to evaluate the effect of transcatheter aortic valve implantation (TAVI) approaches on mortality and identify effect modifiers and predictors for mortality.Background: Alternative access routes to transfemoral (TF) TAVI include the surgical intra‐thoracic direct‐aortic (DA) and transapical (TA) approach. TA TAVI has been associated with a higher mortality rate. We hypothesized that this is related to effect modifiers, in particular the left ventricular ejection fraction (LVEF).Methods: This multicentre study derived its data from prospective registries. To adjust for confounders, we used propensity‐score based, stabilized inverse probability weighted Cox regression models.Results: In total, 5,910 patients underwent TAVI via TF (N = 4,072), DA (N = 524), and TA (N = 1,314) access. Compared to TF, 30‐day mortality was increased among DA (HR 1.87, 95%CI 1.26–2.78, p = .002) and TA (HR 3.34, 95%CI 2.28–4.89, p < .001) cases. Compared to TF, 5‐year mortality was increased among TA cases (HR 1.50, 95%CI 1.24–1.83, p < .001). None of the variables showed a significant interaction between the approaches and mortality. An impaired LVEF (≤35%) increased mortality in all approaches.Conclusions: The surgical intra‐thoracic TA and DA TAVI are both associated with a higher 30‐day mortality than TF TAVI. TA TAVI is associated with a higher 5‐year mortality than TF TAVI. The DA approach may therefore have some advantages over the TA approach when TF access is not feasible.
- Top Cited Papers
- 8 October 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 383 (15) , 1447-1457
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.
- 8 October 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 383 (15) , 1447-1457
Top Cited PapersAspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.
- 9 July 2020
- Published by Springer Nature in Current Cardiology Reports
- Vol. 22 (9) , 1-8
Can TAVR Be Effectively and Safely Performed Without Intraprocedural TEE?
Purpose of Review The TAVR procedure is a well-established therapy for patients with severe aortic stenosis at intermediate/high risk for surgery and a potential treatment for low-risk patients. It is much less invasive with short hospital stays and presents similar results compared with SAVR. Different “minimalist approach strategies” were proposed in order to obtain this performance. In these settings, transesophageal echocardiography (TEE) became less relevant for the TAVR procedure. The present review provides an update regarding the safety of TAVR without intraprocedural TEE. Recent Findings Transthoracic echocardiography and fluoroscopy are the primary imaging tools during TAVR. Several studies proved that TAVR under local anesthesia without TEE is as safe as that performed under TEE guidance. However, not all patients have a proper window for TTE, and particular cases with complex anatomy can benefit from TEE support during the intervention. Summary Intraprocedural TEE no longer plays a crucial role in the TAVR procedure, but in some instances, it remains of great help to detect and avoid complications.
- 9 July 2020
- Published by Springer Nature in Current Cardiology Reports
- Vol. 22 (9) , 1-8
Can TAVR Be Effectively and Safely Performed Without Intraprocedural TEE?
Purpose of Review The TAVR procedure is a well-established therapy for patients with severe aortic stenosis at intermediate/high risk for surgery and a potential treatment for low-risk patients. It is much less invasive with short hospital stays and presents similar results compared with SAVR. Different “minimalist approach strategies” were proposed in order to obtain this performance. In these settings, transesophageal echocardiography (TEE) became less relevant for the TAVR procedure. The present review provides an update regarding the safety of TAVR without intraprocedural TEE. Recent Findings Transthoracic echocardiography and fluoroscopy are the primary imaging tools during TAVR. Several studies proved that TAVR under local anesthesia without TEE is as safe as that performed under TEE guidance. However, not all patients have a proper window for TTE, and particular cases with complex anatomy can benefit from TEE support during the intervention. Summary Intraprocedural TEE no longer plays a crucial role in the TAVR procedure, but in some instances, it remains of great help to detect and avoid complications.